Categories: Artificial IntelligenceBioTechCareDevelopmentDiagnosticsDrugHealthTechLearnPlatformTechnology
Diag-Nose.io is mapping the unified airway to discover life-changing therapies and deliver breakthrough precision respiratory care.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.02.2025 | Seed | $2M | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.03.2025 | ABEL Microsampler® Receives FDA Listing, Expanding Access to Nasal Liquid Biopsies for Research and Diagnostics | Diag-Nose.io Logo
Expanded configuration of the ABEL Microsampler®, ready for laboratory processing and omics analysis
Standardized, non-invasive nasal fluid collection using the ABEL Microsampler® for high-quality biomarker results
ABEL Mi... |
| 05.02.2025 | Diag-Nose.io: Breathing New Life into Respiratory Care with AI Innovation | In a world where chronic respiratory diseases are a silent epidemic, Diag-Nose.io emerges as a beacon of hope. This Seattle-based biotechnology company recently secured $2 million in seed funding, a financial lifeline that promises to resha... |
| 03.02.2025 | Diag-Nose.io Closes $2M Seed Funding | Diag-Nose.io, a Seattle, WA-based respiratory healthcare company, raised $2M in Seed funding.
The round was led by Breakthrough Victoria, with participation from Radar Ventures, a syndicate of physicians from Specialty Physician Associates ... |
| 30.01.2025 | Diag-Nose.io Projected to Enhance Global Respiratory Care Markets Following Oversubscribed $2M Seed Funding | Diag-Nose.io Team Photo
RhinoMAP platform
Diag-Nose.io secures $2M to advance AI in respiratory care, aiming to optimize global disease management and treatment efficacy MELBOURNE, AUSTRALIA, January 30, 2025 /EINPresswire.com/ -- Diag-Nose... |
| - | Diag-Nose Medical | “Diag-Nose Medical” |
Reviews 0
